Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: A single-centre phase 2 trial

BMC Cancer

Volumn 7, Issue , 2007, Pages

  De Maio, Ermelinda ^a   Pacilio, Carmen ^a   Gravina, Adriano ^a   Morabito, Alessandro ^a   Di Rella, Francesca ^a   Labonia, Vincenzo ^a   Landi, Gabriella ^a   Nuzzo, Francesco ^a   Rossi, Emanuela ^a   Silvestro, Pasqualina ^a   Botti, Gerardo ^a   Di Bonito, Maurizio ^a   Curcio, Maria Pia ^a   Formichelli, Franca ^a   La Vecchia, Franca ^a   Staiano, Maria ^a   Maurea, Nicola ^a   D'Aiuto, Giuseppe ^a   D'Aiuto, Massimiliano ^a   Thomas, Renato ^a   Signoriello, Giuseppe ^b   Perrone, Francesco ^a   de Matteis, Andrea ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PAMIDRONIC ACID; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VINBLASTINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; HAIR LOSS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TACHYCARDIA; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; BRAIN TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; FEMALE; GENETICS; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; SURVIVAL; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FATIGUE; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33947632364     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-50     Document Type: Article

References (26)

1. Gusterson BA Gelber RD Goldhirsch A Price KN Save-Soderborgh J Anbazhagan R Styles J Rudenstam CM Golouh R Reed R Prognostic importance of c-erbB-2 expression in breast cancer J Clin Oncol 1992 7 1049-1056
2. Andrulis IL Bull SB Blackstein ME Sutherland D Mak C Sidlofsky S Pritzker KP Hartwick RW Hanna W Lickley L Wilkinson R Qizilbash A Ambus U Lipa M Weizel H Katz A Baida M Mariz S Stoik G Dacamara P Strongitharm D Geddie W McCready D neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer J Clin Oncol 1998 16 1340-1349 9552035
3. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001 344 783-792 11248153 10.1056/ NEJM200103153441101
4. Osoba D Slamon DJ Burchmore M Murphy M Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer J Clin Oncol 2002 20 14 3106-3113 12118024 10.1200/JCO.2002.03.090
5. Pegram M Hsu S Lewis G Pietras R Beryt M Sliwkowski M Coombs D Baly D Kabbinavar F Slamon D Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 1999 18 2241-2251 10327070 10.1038/sj.onc.1202526
6. Baselga J Norton L Albanell J Kim YM Mendelsohn J Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Research 1998 58 2825-2831 9661897
7. Burstein HJ Kuter I Campos SM Gelman RS Tribou L Parker LM Manola J Younger J Matulonis U Bunnell CA Partridge AH Richardson PG Clarke K Shulman LN Winer EP Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 2001 19 2722-2730 11352965
8. Jahanzeb M Mortimer JE Yunus F Irwin DH Speyer J Koletsky AJ Klein P Sabir T Kronish L Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer Oncologist 2002 7 5 410-417 12401903 10.1634/theoncologist.7-5-410
9. Leyland-Jones B Gelmon K Ayoub JP Arnold A Verma S Dias R Ghahramani P Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 2003 21 21 3965-71 14507946 10.1200/JCO.2003.12.109
10. Ellis IO Dowsett M Bartlett J Walker R Cooke T Gullick W Gusterson B Mallon E Lee PB Recommendations for HER2 testing in the UK J Clin Pathol 2000 53 12 890-2 11265171 10.1136/jcp.53.12.890
11. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 2000 92 205-216 10655437 10.1093/jnci/92.3.205
12. Kaplan EL Meier P Non parametric estimation from incomplete observation J Am Stat Assoc 1958 53 457-81 10.2307/2281868
13. Chan A A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer Ann Oncol 2007, Jan 29
14. Bartsch R Wenzel C Pluschnig U Hussian D Sevelda U Locker GJ Mader R Zielinski CC Steger GG Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: Results from a pilot trial Cancer Chemother Pharmacol 2006 57 5 554-8 16133525 10.1007/s00280-005-0092-6
15. Baselga J Carbonell X Castañeda-Soto NJ Clemens M Green M Harvey V Morales S Barton C Ghahramani P Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule J Clin Oncol 2005 23 10 2162-71 15800309 10.1200/JCO.2005.01.014
16. Burstein HJ Lieberman G Slamon DJ Winer EP Klein P Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy Ann Oncol 2005 16 1772-1777 16150805 10.1093/annonc/mdi371
17. Bendell JC Domchek SM Burstein HJ Harris L Younger J Kuter I Bunnell C Rue M Gelman R Winer E Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 2003 97 2972-2977 12784331 10.1002/cncr.11436
18. Shmueli E Wigler N Inbar M Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment Eur J Cancer 2004 40 379-382 14746856 10.1016/ j.ejca.2003.09.018
19. Lin NU Bellon JR Winer EP CNS metastases in breast cancer J Clin Oncol 2004 22 3608-3617 15337811 10.1200/JCO.2004.01.175
20. Mayer RJ Berkowitz RS Griffiths CT Central nervous system involvement by ovarian carcinoma: A complication of prolonged survival with metastatic disease Cancer 1978 41 776-783 630551 10.1002/ 1097-0142(197802)41:2<776::AID-CNCR2820410253>3.0.CO;2-E
21. Crivellari D Pagani O Veronesi A Lombardi D Nole F Thurlimann B Hess D Borner M Bauer J Martinelli G Graffeo R Sessa C Goldhirsch A High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel Ann Oncol 2001 12 353-356 11332148 10.1023/A:1011132609055
22. Marty M Cognetti M Maraninchi D Snyder R Mauriac L Tubiana-Hulin M Chan S Grimes D Anton A Lluch A Kennedy J O'Byrne K Conte P Green M Ward C Mayne K Extra JM Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group J Clin Oncol 2005 23 4265-4274 15911866 10.1200/JCO.2005.04.173
23. Piccart-Gebhart MJ Procter M Leyland-Jones B Goldhirsch A Untch M Smith I Gianni L Baselga J Bell R Jackisch C Cameron D Dowsett M BarrioS CH Steger G Huang CS Andersson M Inbar M Lichinitser M Láng I Nitz U Iwata H Thomssen C Lohrisch C Suter TM Rüschoff J Süto T Greatorex V Ward C Straehle C McFadden E Dolci S Gelber RD for the Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer N Engl J Med 2005 353 16 1659-72 16236737 10.1056/NEJMoa052306
24. Romond EH Perez EA Bryant J Suman VJ Geyer CE Davidson NE Tan-Chiu E Martino S Paik S Kaufman PA Swain SM Pisansky TM Fehrenbacher L Kutteh LA Vogel VG Visscher DW Yothers G Jenkins RB Brown AM Dakhil SR Mamounas EP Lingle WL Klein PM Ingle JN Wolmark N Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer N Engl J Med 2005 353 16 1673-84 16236738 10.1056/NEJMoa052122
25. Geyer E Forster J Lindquist D Chan S Romieu G Pienkowski T Jagiello-Gruszfeld A Crown J Chan A Kaufman B Skarlos D Campone M Davidson N Berger M Oliva C Rubin SD Stein S Cameron D Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 2006 355 2733-43 17192538 10.1056/NEJMoa064320
26. Pegram MD Konecny GE O'Callaghan C Beryt M Pietras R Slamon DJ Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst 2004 96 10 739-49 15150302